Osilodrostat
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cushing's Syndrome
Conditions
Cushing's Syndrome, Ectopic Corticotropin Syndrome, Adrenal Adenoma, Adrenal Carcinoma, AIMAH, PPNAD
Trial Timeline
Sep 24, 2015 → Oct 29, 2018
NCT ID
NCT02468193About Osilodrostat
Osilodrostat is a phase 2 stage product being developed by Novartis for Cushing's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02468193. Target conditions include Cushing's Syndrome, Ectopic Corticotropin Syndrome, Adrenal Adenoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02399202 | Phase 1 | Completed |
| NCT02468193 | Phase 2 | Completed |
| NCT02372084 | Phase 1 | Completed |
Competing Products
18 competing products in Cushing's Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD4017 and prednisolone + Placebo Oral Tablet and prednisolone | AstraZeneca | Phase 2 | 52 |
| pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mg | Novartis | Phase 3 | 77 |
| Pasireotide sub-cutaneous | Novartis | Phase 3 | 77 |
| osilodrostat + osilodrostat Placebo | Novartis | Phase 3 | 77 |
| Pasireotide | Novartis | Phase 3 | 77 |
| Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + Metformin | Novartis | Approved | 85 |
| SOM230 s.c. | Novartis | Phase 2 | 52 |
| Lu AG13909 | Lundbeck | Phase 2 | 49 |
| Osilodrostat | Recordati | Pre-clinical | 20 |
| Pasireotide + Cabergoline + Pasireotide LAR | Recordati | Approved | 82 |
| osilodrostat | Recordati | Phase 2 | 49 |
| Osilodrostat | Recordati | Pre-clinical | 20 |
| mifepristone | Corcept Therapeutics | Phase 3 | 72 |
| CORT125134 | Corcept Therapeutics | Phase 2 | 47 |
| Cushing's syndrome confirmation | Corcept Therapeutics | Pre-clinical | 18 |
| Mifepristone | Corcept Therapeutics | Phase 3 | 72 |
| mifepristone | Corcept Therapeutics | Phase 3 | 72 |
| mifepristone | Corcept Therapeutics | Phase 3 | 72 |